| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02614560 Details | 2019-01-09 Interventional | 1/2 | 14 | Fludarabine Melphalan Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | - No patients were enrolled in Phase 2 due to study termination. | |||
| NCT02313909 2013-000768-27 Details | 2019-01-09 Interventional | 3 | [3 Refs] | 7213 | Aspirin Rivaroxaban Embolic Stroke Embolism Stroke | Study halted early due to no efficacy improvement over aspirin at an interim analysis and very
little chance of showing overall benefit if study were completed Study terminated early due to no efficacy improvement over aspirin at the second interim analysis and very little chance of showing overall benefit if the study were completed. | ||
| NCT01891669 Details | 2019-01-09 Interventional | 1 | 26 | PF-06263507 Breast Neoplasm… Carcinoma, Non-… Neoplasms Ovarian Neoplas… Carcinoma, Non … | The study was terminated on June 23, 2015 due to the company's change in prioritization for the
portfolio and is not due to any safety concerns. This study was terminated prematurely before treatment in Part 2 started due to a business-related decision. | |||
| NCT02299635 2014-002286-30 Details | 2019-01-08 Interventional | 2 | 19 | Nirogacestat Breast Neoplasm… Triple Negative… | The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014
development. There were no safety/efficacy concerns behind the decision. This study was terminated prematurely based on project re-prioritization by the Sponsor and was not due to any safety concerns or regulatory actions. | |||
| NCT02008006 2013-000076-16 Details | 2019-01-08 Interventional | 2 | 21 | Bendamustine Hy… Cytarabine Etoposide Melphalan Lymphoma Lymphoma, Folli… Follicular Lymp… | Insufficient recruitment and unavailability of the treatment - | |||
| NCT01925274 2013-002095-40 Details | 2019-01-08 Interventional | 2 | 19 | Cetuximab Gedatolisib Irinotecan Colorectal Neop… Metastatic Colo… | Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no
safety or efficacy issues that contributed to this decision. This study was terminated by sponsor due to strategic reasons and not due to any safety or efficacy concerns with treatment of PF-05212384. | |||
| NCT01457131 Details | 2019-01-08 Interventional | 1 | 2 | Cyclophosphamid… Fludarabine Kidney Neoplasm… Melanoma Neoplasm Metast… Neoplasms Neoplasms, Seco… Metastatic Canc… Metastatic Mela… Metastatic Rena… | - - | |||
| NCT01441414 2011-002190-33 Details | 2019-01-08 Interventional | 2 | 18 | Axitinib Carcinoma Carcinoma, Rena… Metastatic Rena… | See termination reason in detailed description. On 06 Nov 2012, based on Part I safety findings and due to strategic considerations, Pfizer decided not to open enrolment onto Part II of the study and terminated the study. For primary OM, AEs reported in ≥2 participants overall are presented. | |||
| NCT01420081 2011-003062-32 Details | 2019-01-08 Interventional | 2 | 67 | Gedatolisib Endometrial Neo… | See termination reason in detailed description. - | |||
| NCT01232556 2010-020147-12 Details | 2019-01-08 Interventional | 3 | 338 | Bendamustine Hy… Gemcitabine Inotuzumab Ozog… Rituximab Aggression Lymphoma Lymphoma, Non-H… | The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety
issues were identified. Interpretation of the results is limited by the small number of subjects analyzed and follow-up period was shortened due to the early termination of the study. Adverse Events were calculated using the safety populations. | |||
| NCT02567279 Details | 2019-01-07 Interventional | 3 | 2 | Denosumab Anorexia Anorexia Nervos… | Great difficulties were encountered during recruitment, for fear Denozumab. Only 2 patients
have been included since the study start. - | |||
| NCT03092765 Details | 2019-01-04 Interventional | 2 | 29 | Quetmolimab Cholangitis Liver Cirrhosis… Primary Biliary… | Sponsor's decision (non-safety related) - | |||
| NCT02605122 Details | 2019-01-03 Interventional | 2/3 | 97 | Amoxicillin Amoxicillin-Pot… Ampicillin Azithromycin Ceftriaxone Clavulanic Acid Clavulanic Acid… Erythromycin Erythromycin Es… Erythromycin Et… Erythromycin la… Erythromycin st… Solithromycin Pneumonia Pneumonia, Bact… Community-acqui… | Development not proceeding The study was discontinued early due to a company business decision. Study discontinuation was not related to safety or tolerability. | |||
| NCT02520518 Details | 2019-01-03 Interventional | 2 | 9 | Dapagliflozin Body Weight Weight Loss | Designed a new modified/simplified protocol see NCT 03180489 - | |||
| NCT03063242 Details | 2018-12-31 Interventional | 2 | 4 | Sargramostim Kidney Diseases Kidney Transpla… | Insufficient resources necessary for completion. - | |||
| NCT01722292 2012-003174-83 Details | 2018-12-28 Interventional | 1/2 | 26 | Carboplatin Etoposide Small Cell Lung… | Change in clinical strategy. Due to strategic reasons, the Phase 2 portion was not initiated, and further clinical development was stopped. | |||
| NCT02050321 Details | 2018-12-26 Interventional | 2 | 2 | Acitretin Vemurafenib Melanoma Malignant Melan… | Pharmaceutical company pulled support for the trial. - | |||
| NCT03026023 Details | 2018-12-20 Interventional | 4 | 0 | Grazoprevir Ribavirin Hepatitis Hepatitis C Cardiac Transpl… | moved forward with another protocol utilizing pan genotypic treatment once it became
commercially available and FDA approved - | |||
| NCT02646774 Details | 2018-12-20 Interventional | 4 | 43 | Micafungin Aspergillosis Invasive Asperg… | Due to administrative reasons - | |||
| NCT01982071 Details | 2018-12-20 Interventional | 4 | 59 | Micafungin Candidemia Candidiasis Candidiasis, In… | Due to administrative reasons - |